Investigational drug · Phase 3
NTCB02-1
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Parenteral Nutrition.
Phase 3Last checked: Nov 19, 2026Latest source record: Jan 7, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "NTCB02-1"
First trial start
2024
Dec 4, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NTCB02-1", any sponsor or status.
Conditions studied
As listed on its trial records.
- Parenteral Nutrition
Largest trials
Live from ClinicalTrials.gov: studies naming "NTCB02-1" as an intervention, largest first.
- Clinical Trial to Evaluate the Safety and Efficacy of NTCB02-1 in Patients Who Require Parenteral NutritionPivotal-lookingRecruiting
Yuhan CorporationIndustry
NCT06625957 · 60 participants (planned) · Start Dec 4, 2024 · Primary completion Jul 18, 2025
Drug: NTCB02-1; NTCB-C · For: Parenteral Nutrition
Sites: Gyeonggi-do, South Korea; Jeollanam-do, South Korea; Jeollabuk-do, South Korea · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Parenteral Nutrition
- NTCB01-1Phase 31 trial
Yuhan Corporation · Parenteral Nutrition
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.